Home > Oncology > ASCO 2019 > Lung Cancer > Novel RET Inhibitor BLU-667 Offers Promise for RET+ Advanced NSCLC

Novel RET Inhibitor BLU-667 Offers Promise for RET+ Advanced NSCLC

Presented By
Dr Justin F. Gainor, Massachusetts General Hospital, USA
Conference
ASCO 2019
Trial
Phase 1, ARROW

Medical writer: Dave Levitan

The novel selective RET inhibitor BLU-667 demonstrated promising anti-tumour activity and was well tolerated in patients with RET fusion–positive advanced non–small cell lung cancer (NSCLC), according to a study presented on June 3 (Abstract 9008).

Approximately 1% to 2% of patients with NSCLC have tumours harboring RET fusions. “In contrast to other oncogenic fusions in NSCLC, such as ALK…there are currently no [U.S. Food and Drug Administration (FDA)]–approved selective RET inhibitors to date,” Justin F. Gainor, MD, of Massachusetts General Hospital, said, during the presentation of the results of the ongoing ARROW phase I dose-escalation and expansion study.

Patients with NSCLC have had low response rates to chemotherapy and immune checkpoint inhibition, and multikinase inhibitors have demonstrated low activity and high levels of off-target toxicity. BLU-667 potently and selectively inhibits ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on